202 related articles for article (PubMed ID: 33117701)
1. Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma.
Ueda Y; Enokida T; Okano S; Fujisawa T; Ito K; Tahara M
Front Oncol; 2020; 10():571304. PubMed ID: 33117701
[No Abstract] [Full Text] [Related]
2. Phase II trial of combination treatment with paclitaxel, carboplatin and cetuximab (PCE) as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CSPOR-HN02).
Tahara M; Kiyota N; Yokota T; Hasegawa Y; Muro K; Takahashi S; Onoe T; Homma A; Taguchi J; Suzuki M; Minato K; Yane K; Ueda S; Hara H; Saijo K; Yamanaka T
Ann Oncol; 2018 Apr; 29(4):1004-1009. PubMed ID: 29408977
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study.
Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Motegi A; Zenda S; Akimoto T; Tahara M
Front Oncol; 2022; 12():951387. PubMed ID: 36033502
[TBL] [Abstract][Full Text] [Related]
4. Weekly paclitaxel, carboplatin and cetuximab (PCE) combination followed by nivolumab for recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
Takeshita N; Enokida T; Okano S; Fujisawa T; Wada A; Sato M; Tanaka H; Tanaka N; Onaga R; Hoshi Y; Sakashita S; Ishii G; Tahara M
Oral Oncol; 2023 Dec; 147():106615. PubMed ID: 37931493
[TBL] [Abstract][Full Text] [Related]
5. Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Carinato H; Burgy M; Ferry R; Fischbach C; Kalish M; Guihard S; Brahimi Y; Flesch H; Bronner G; Schultz P; Frasie V; Thiéry A; Demarchi M; Petit T; Jung AC; Wagner P; Coliat P; Borel C
Front Oncol; 2021; 11():714551. PubMed ID: 34778031
[TBL] [Abstract][Full Text] [Related]
6. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials.
Fang W; Yang Y; Ma Y; Hong S; Lin L; He X; Xiong J; Li P; Zhao H; Huang Y; Zhang Y; Chen L; Zhou N; Zhao Y; Hou X; Yang Q; Zhang L
Lancet Oncol; 2018 Oct; 19(10):1338-1350. PubMed ID: 30213452
[TBL] [Abstract][Full Text] [Related]
7. Multicenter, phase II study of cetuximab in combination with carboplatin in patients with recurrent or metastatic nasopharyngeal carcinoma.
Chan AT; Hsu MM; Goh BC; Hui EP; Liu TW; Millward MJ; Hong RL; Whang-Peng J; Ma BB; To KF; Mueser M; Amellal N; Lin X; Chang AY
J Clin Oncol; 2005 May; 23(15):3568-76. PubMed ID: 15809453
[TBL] [Abstract][Full Text] [Related]
8. Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial.
Guigay J; Aupérin A; Fayette J; Saada-Bouzid E; Lafond C; Taberna M; Geoffrois L; Martin L; Capitain O; Cupissol D; Castanie H; Vansteene D; Schafhausen P; Johnson A; Even C; Sire C; Duplomb S; Evrard C; Delord JP; Laguerre B; Zanetta S; Chevassus-Clément C; Fraslin A; Louat F; Sinigaglia L; Keilholz U; Bourhis J; Mesia R; ; ;
Lancet Oncol; 2021 Apr; 22(4):463-475. PubMed ID: 33684370
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Cetuximab Combined with Paclitaxel in Patients with Recurrent Salivary Gland Carcinoma: A Retrospective Observational Study.
Sato R; Yuasa R; Kumai T; Wakisaka R; Komatsuda H; Kono M; Yamaki H; Ishida Y; Wada T; Takahara M; Katada A
ORL J Otorhinolaryngol Relat Spec; 2024; 86(1):41-49. PubMed ID: 38091970
[TBL] [Abstract][Full Text] [Related]
10. A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck.
Enokida T; Ogawa T; Homma A; Okami K; Minami S; Nakanome A; Shimizu Y; Maki D; Ueda Y; Fujisawa T; Motegi A; Ohkoshi A; Taguchi J; Ebisumoto K; Nomura S; Okano S; Tahara M
Cancer Med; 2020 Mar; 9(5):1671-1682. PubMed ID: 31943834
[TBL] [Abstract][Full Text] [Related]
11. Bevacizumab versus placebo in combination with paclitaxel and carboplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase II trial.
Zhou T; Yang Y; Ma S; Lin L; Zhou T; Zhang C; Ding X; Wang R; Feng G; Chen Y; Xu R; Huang Y; Zhang L
ESMO Open; 2021 Dec; 6(6):100313. PubMed ID: 34837744
[TBL] [Abstract][Full Text] [Related]
12. Triplet combination of gemcitabine, paclitaxel, and carboplatin followed by maintenance 5-fluorouracil and folinic acid in patients with metastatic nasopharyngeal carcinoma.
Leong SS; Wee J; Rajan S; Toh CK; Lim WT; Hee SW; Tay MH; Poon D; Tan EH
Cancer; 2008 Sep; 113(6):1332-7. PubMed ID: 18615622
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Skarlos D; Athanassiades A; Kalogera-Fountzila A; Samantas E; Bacoyiannis C; Nicolaou A; Dombros N; Briasoulis E; Dinopoulou M; Stathopoulos G; Pavlidis N; Kosmidis P; Daniilidis J
Ann Oncol; 1997 May; 8(5):451-5. PubMed ID: 9233524
[TBL] [Abstract][Full Text] [Related]
14. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
15. Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trial.
Pignata S; Lorusso D; Joly F; Gallo C; Colombo N; Sessa C; Bamias A; Salutari V; Selle F; Frezzini S; De Giorgi U; Pautier P; Bologna A; Orditura M; Dubot C; Gadducci A; Mammoliti S; Ray-Coquard I; Zafarana E; Breda E; Favier L; Ardizzoia A; Cinieri S; Largillier R; Sambataro D; Guardiola E; Lauria R; Pisano C; Raspagliesi F; Scambia G; Daniele G; Perrone F;
Lancet Oncol; 2021 Feb; 22(2):267-276. PubMed ID: 33539744
[TBL] [Abstract][Full Text] [Related]
16. A randomized, phase 2 study of cetuximab plus cisplatin with or without paclitaxel for the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck.
Bossi P; Miceli R; Locati LD; Ferrari D; Vecchio S; Moretti G; Denaro N; Caponigro F; Airoldi M; Moro C; Vaccher E; Sponghini A; Caldara A; Rinaldi G; Ferrau F; Nolè F; Lo Vullo S; Tettamanzi F; Hollander L; Licitra L
Ann Oncol; 2017 Nov; 28(11):2820-2826. PubMed ID: 28950305
[TBL] [Abstract][Full Text] [Related]
17. Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial).
Tsakonas G; Specht L; Kristensen CA; Moreno MHC; Cange HH; Soderstrom K; Friesland S
Cancers (Basel); 2020 Oct; 12(11):. PubMed ID: 33114379
[TBL] [Abstract][Full Text] [Related]
18. Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study.
Kodama H; Kadowaki S; Nakazawa T; Matsubara Y; Narita Y; Honda K; Masuishi T; Taniguchi H; Ando M; Koide Y; Tachibana H; Kodaira T; Sawabe M; Terada H; Beppu S; Nishikawa D; Suzuki H; Hanai N; Muro K
Anticancer Res; 2024 Mar; 44(3):1227-1232. PubMed ID: 38423663
[TBL] [Abstract][Full Text] [Related]
19. Paclitaxel, carboplatin, and gemcitabine in metastatic nasopharyngeal carcinoma: a Phase II trial using a triplet combination.
Leong SS; Wee J; Tay MH; Toh CK; Tan SB; Thng CH; Foo KF; Lim WT; Tan T; Tan EH
Cancer; 2005 Feb; 103(3):569-75. PubMed ID: 15611975
[TBL] [Abstract][Full Text] [Related]
20. Triplet combination with paclitaxel, cisplatin and 5-FU is effective in metastatic and/or recurrent nasopharyngeal carcinoma.
Chen C; Wang FH; An X; Luo HY; Wang ZQ; Liang Y; Zhang L; Li YH
Cancer Chemother Pharmacol; 2013 Feb; 71(2):371-8. PubMed ID: 23143190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
